Akademik Veri Yönetim Sistemi
Current Research in Pharmacy and Pharmaceutical Sciences III ( AYBAK 2025 Fall), Cem Yamalı,Merve Nenni, Editör, Akademisyen Kitabevi, Ankara, ss.13-25, 2025
Male sexual dysfunction affects a person’s health and quality of life. ED and PE are the most common disorders in the global population. Thoroughly investigating patients for the coexistence of ED and PE, developing treatments accordingly, and addressing the disadvantages of existing treatment modalities will increase overall treatment success. Therefore, combination formulations of medications used in the treatment of ED and PE should be developed. Patient compliance should be increased by eliminating the disadvantages of traditional dosage forms, such as difficulty in use, delayed onset of effects, and the high dose required to achieve the desired effect. Nanotechnology should be applied to improve the solubility and bioavailability of existing pharmaceutical agents, enabling innovative dosage forms to be formulated. This allows for earlier onset of effects and ease of use. Furthermore, reducing the dosage administered in commercial products increases profit margins for manufacturers and reduces the likelihood of toxic and side effects in patients. Furthermore, the frequency of coexisting conditions should not be overlooked, and combination medications should be offered in innovative dosage forms.